Skip to main content
Have a personal or library account? Click to login
Di-Chimeric Cell Therapy Derived From Hematopoietic and Mesenchymal Stem Cells Promotes Immune Tolerance and Extends Vascularized Composite Allograft Survival Cover

Di-Chimeric Cell Therapy Derived From Hematopoietic and Mesenchymal Stem Cells Promotes Immune Tolerance and Extends Vascularized Composite Allograft Survival

Open Access
|Apr 2026

References

  1. Arslan E, Klimczak A, Siemionow M (2007) Chimerism induction in vascularized bone marrow transplants augmented with bone marrow cells. Microsurgery 27:190–199. https://doi.org/10.1002/micr.20330
  2. Bastani S, Staal FJT, Canté-Barrett K (2023) The quest for the holy grail: Overcoming challenges in expanding human hematopoietic stem cells for clinical use. Stem Cell Investig 10:15. https://doi.org/10.21037/sci-2023-016
  3. Cohen JL, Trenado A, Vasey D et al. (2002) CD4+ CD25+ immunoregulatory T cells: New therapeutics for graft-versus-host disease. J Exp Med 196:401–406. https://doi.org/10.1084/jem.20020090
  4. Cwykiel J, Jundzill A, Klimczak A et al. (2021a) Donor-recipient chimeric cells induce chimerism and extend survival of vascularized composite allografts. Arch Immunol Ther Exp 69:13. https://doi.org/10.1007/s00005-021-00614-9
  5. Cwykiel J, Madajka-Niemeyer M, Siemionow M (2021b) Development of donor–recipient chimeric cells of bone marrow origin as a novel approach for tolerance induction in transplantation. Stem Cell Investig 8:8. https://doi.org/10.21037/sci-2020-044
  6. Cyran M, Stawarz K, Chambily L et al. (2024) Assessment of hematopoietic response to total body irradiation in a rat experimental model. Ann Plast Surg 93:100–106. https://doi.org/10.1097/SAP.0000000000003962
  7. de Vasconcelos P, Lacerda JF (2022) Hematopoietic stem cell transplantation for neurological disorders: A focus on inborn errors of metabolism. Front Cell Neurosci 16:895511. https://doi.org/10.3389/fncel.2022.895511
  8. Doglio M, Crossland RE, Alho AC et al. (2022) Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease. Front Immunol 13:1045168. https://doi.org/10.3389/fimmu.2022.1045168
  9. Eldaly AS, Avila FR, Torres-Guzman RA et al. (2024) Cell-based therapies induce tolerance of vascularized composite allotransplants: A systematic review. J Surg Res 300:389–401. https://doi.org/10.1016/j.jss.2024.04.079
  10. Hall BM (2016) CD4+CD25+ T regulatory cells in transplantation tolerance: 25 years on. Transplantation 100:2533–2547. https://doi.org/10.1097/TP.0000000000001436
  11. Heyes R, Iarocci A, Tchoukalova Y et al. (2016) Immunomodulatory role of mesenchymal stem cell therapy in vascularized composite allotransplantation. J Transplant 2016:6951693. https://doi.org/10.1155/2016/6951693
  12. Hivelin M, Klimczak A, Cwykiel J et al. (2016) Immunomodulatory effects of different cellular therapies of bone marrow origin on chimerism induction and maintenance across MHC barriers in a face allotransplantation model. Arch Immunol Ther Exp 64:299–310. https://doi.org/10.1007/s00005-015-0380-8
  13. Jundziłł A, Klimczak A, Sonmez E et al. (2021) The positive impact of donor bone marrow cells transplantation into immunoprivileged compartments on the survival of vascularized skin allografts. Arch Immunol Ther Exp 69:28. https://doi.org/10.1007/s00005-021-00631-8
  14. Klimczak A, Unal S, Jankowska A et al. (2007) Donor-origin cell engraftment after intraosseous or intravenous bone marrow transplantation in a rat model. Bone Marrow Transplant 40:373–380. https://doi.org/10.1038/sj.bmt.1705743
  15. Li Z, Czechowicz A, Scheck A et al. (2019) Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody–drug-conjugate conditioning in MHC-mismatched allotransplantation. Nat Commun 10:616. https://doi.org/10.1038/s41467-018-08202-w
  16. Ménard C, Tarte K (2013) Immunoregulatory properties of clinical grade mesenchymal stromal cells: Evidence, uncertainties, and clinical application. Stem Cell Res Ther 4:64. https://doi.org/10.1186/scrt214
  17. Okeke EB, Uzonna JE (2019) The pivotal role of regulatory T cells in the regulation of innate immune cells. Front Immunol 10:680. https://doi.org/10.3389/fimmu.2019.00680
  18. Ou Q, Power R, Griffin MD (2023) Revisiting regulatory T cells as modulators of innate immune response and inflammatory diseases. Front Immunol 14:1287465. https://doi.org/10.3389/fimmu.2023.1287465
  19. Ruiz R, Kirk AD (2015) Long-Term Toxicity of Immunosuppressive Therapy. In: Transplantation of the Liver (Third Edition). Philadelphia, PA, USA: W.B. Saunders, pp.1354–1363. https://doi:10.1016/B978-1-4557-0268-8.00097-X
  20. Sakaguchi S, Yamaguchi T, Nomura T et al. (2008) Regulatory T cells and immune tolerance. Cell 133:775–787. https://doi.org/10.1016/j.cell.2008.05.009
  21. Siemionow M, Klimczak A (2013) Chimerism-based experimental models for tolerance induction in vascularized composite allografts: Cleveland clinic research experience. Clin Dev Immunol 2013:831410. https://doi.org/10.1155/2013/831410
  22. Siemionow M, Klimczak A, Unal S (2005) Different routes of donor-derived hematopoietic stem cell transplantation for donor-specific chimerism induction across MHC barrier. Transplant Proc 37:62–64. https://doi.org/10.1016/j.transproceed.2004.12.216
  23. Siemionow M, Nasir S (2007) Chimerism and bone marrow-based therapies in transplantation. Microsurgery 27:510–521. https://doi.org/10.1002/micr.20395
  24. Siemionow M, Ortak T, Izycki D et al. (2002) Induction of tolerance in composite-tissue allografts. Transplantation 74:1211–1217. https://doi.org/10.1097/00007890-200211150-00002
  25. Siemionow M, Rampazzo A, Gharb BB et al. (2016) The reversed paradigm of chimerism induction: Donor conditioning with recipient-derived bone marrow cells as a novel approach for tolerance induction in vascularized composite allotransplantation. Microsurgery 36:676–683. https://doi.org/10.1002/micr.30041
  26. Song N, Scholtemeijer M, Shah K (2020) Mesenchymal stem cell immunomodulation: Mechanisms and therapeutic potential. Trends Pharmacol Sci 41:653–664. https://doi.org/10.1016/j.tips.2020.06.009
  27. Spaggiari GM, Capobianco A, Abdelrazik H et al. (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production. Blood 111:1327–1333. https://doi.org/10.1182/blood-2007-02-074997
  28. Yu S, Lu J (2023) The potential of mesenchymal stem cells to induce immune tolerance to allogeneic transplants. Transpl Immunol 81:101939. https://doi.org/10.1016/j.trim.2023.101939
  29. Zhang W, Wang Y, Zhong F et al. (2023) Donor derived hematopoietic stem cell niche transplantation facilitates mixed chimerism mediated donor specific tolerance. Front Immunol 14:1093302. https://doi.org/10.3389/fimmu.2023.1093302
  30. Zor F, Karagoz H, Erdemir AT et al. (2016) Reflectance confocal microscopy as a useful diagnostic tool for monitoring skin-containing vascularized composite allograft rejection: A preliminary study in rats. Microsurgery 36:144–151. https://doi.org/10.1002/micr.22419
Language: English
Submitted on: Dec 19, 2025
Accepted on: Feb 23, 2026
Published on: Apr 9, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2026 Maria Siemionow, Safak Halil Uygur, Katarzyna Stawarz, Lucile Chambily, Katarzyna Budzynska, Weronika Radecka, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.